Recombinant hemoglobin betaG83C-F41Y

Area of Science:

• Biochemistry
• Biotechnology
• Biophysics

Background:

• Acellular hemoglobin solutions face challenges with vasoactivity due to their molecular size.
• Increasing the molecular size of hemoglobin carriers is a strategy to mitigate vasoactivity.
• Recombinant hemoglobin (rHb) engineering offers potential solutions for blood substitutes.

Purpose of the Study:

• To engineer a stable, larger molecular weight hemoglobin variant.
• To assess the oxygen-binding properties and stability of the engineered hemoglobin.
• To evaluate the potential of the engineered hemoglobin as an oxygen carrier with reduced vasoactivity.

Main Methods:

• Disulfide bond formation to create stable octameric hemoglobin (Hb) from recombinant tetramers (rHb betaG83C-F41Y).
• Oxygen equilibrium curve analysis to determine oxygen affinity and cooperativity.
• Kinetic studies (CO rebinding, auto-oxidation) and size exclusion chromatography to assess stability.
• Haptoglobin binding assays and resistance tests against plasma reducing agents.

Main Results:

• Successfully engineered a stable 129 kDa octameric rHb betaG83C-F41Y.
• Octameric rHb exhibited increased oxygen affinity and decreased cooperativity compared to tetramers.
• Demonstrated stability against dissociation, haptoglobin binding, and plasma reducing agents.
• Spontaneous disulfide bond formation under air and resistance to reduction by glutathione.

Conclusions:

• The engineered octameric rHb betaG83C-F41Y represents a stable acellular hemoglobin with potentially reduced vasoactivity.
• Its enhanced stability and altered oxygen-binding properties make it a promising candidate for blood substitute applications.
• Further studies are warranted to confirm its in vivo efficacy and safety profile.